The "Global Viral Vectors Market 2022-2026" report has been added to ResearchAndMarkets.com's offering. The viral vectors market is poised to grow by $490.64 mn during 2022-2026, accelerating at a
/PRNewswire/ The viral vectors market growth will be driven by the rising prevalence of chronic diseases. The prevalence and incidence of life-threatening.
Oxford Biomedica (OTCMKTS:OXBDF – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, “Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford […]
Equities Research Analysts’ upgrades for Friday, May 27th: Atlas Air Worldwide (NASDAQ:AAWW) was upgraded by analysts at StockNews.com from a hold rating to a buy rating. AutoNation (NYSE:AN) was upgraded by analysts at StockNews.com from a buy rating to a strong-buy rating. Auto Trader Group (OTCMKTS:ATDRY) was upgraded by analysts at JPMorgan Chase & Co. […]
LONDON (dpa-AFX) - Oxford Biomedica Plc (OXB) a British gene and cell therapy company, said on Monday that after over 13 years of service, its Chief Executive Officer or CEO John Dawson, has expressed